Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CDK4
REST API REST API
Homo sapiens
CDK4 is differentially expressed in 290 experiments: 136 organism parts: ovary, blood, ... (134 more);, 213 disease states: normal, lung adenocarcinoma, ... (211 more);, 95 cell types 337 cell lines 40 compound treatments and 77 other conditions.
Synonyms PSK-J3
Orthologs CDC28 (Saccharomyces cerevisiae)   LOC100362034 (Rattus norvegicus)   ENSCING00000002540 (Ciona intestinalis)   CDK4_BOVIN (Bos taurus)   CDK4 (Danio rerio)   F1LXG5_RAT (Rattus norvegicus)   Cdk4 (Mus musculus)   Cdk4 (Drosophila melanogaster)   cdk4 (Xenopus laevis)   ENSBTAG00000046091 (Bos taurus)   ENSBTAG00000045571 (Bos taurus)   LOC612475 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cyclin-dependent protein kinase activity, cytosol, cell division, protein binding, cytoplasm, regulation of cell proliferation, positive regulation of cell proliferation, membrane, mitotic cell cycle, protein tyrosine kinase activity, G1 phase of mitotic cell cycle, ATP binding, cell cycle, transferase activity, transferring phosphorus-containing groups, regulation of cell cycle, G1/S transition of mitotic cell cycle, nucleus, regulation of gene expression, nucleotide binding, kinase activity, transcription factor complex, protein serine/threonine kinase activity, response to drug, chromatin, nucleoplasm, S phase of mitotic cell cycle, signal transduction, protein kinase activity, nucleolus, nuclear membrane, positive regulation of fibroblast proliferation, cyclin-dependent protein kinase holoenzyme complex, protein phosphorylation
InterPro Term Aminoglycoside_PTrfase, Prot_kinase_cat_dom, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession P11802, Q6LC83, B4DNF9, Q96BE9, F8VZZ0, F8VTV8, F8VZ51, F8VYY1, F8VZ13, F8VYH9, F8VXD2, F8VWX7, F8W1L8
Gene-Disease Assocation MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 3; CMM3
Search EB-eye ENSG00000135446
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-6573, E-MEXP-433, E-GEOD-3526, E-MTAB-62, E-GEOD-18105, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, ... (35 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-5823, E-GEOD-19639
SW48
1
E-MTAB-37
DU-145
1
E-MEXP-2172
NA18516
1
E-GEOD-19480
Ag11498
1
E-MTAB-62
Jurkat
1
E-MEXP-2197
331 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-3920, E-GEOD-4219, E-GEOD-13909, E-GEOD-20677, ... (46 experiments)

Factor Value U/D Experiments
monocyte
1
4
E-GEOD-5099, E-MEXP-583, E-MEXP-2019, E-GEOD-995, E-GEOD-8286 ... (5 experiments)
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
1
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
eosinophil
1
E-GEOD-3982
89 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-12254, E-MTAB-62, ... (66 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-MTAB-57, E-GEOD-3726
prostate carcinoma
3
E-MTAB-62, E-GEOD-96, E-MEXP-2034
lung adenocarcinoma
1
3
E-MTAB-37, E-MEXP-231, E-MTAB-62, E-GEOD-2514
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
207 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-697, E-GEOD-3720, ... (32 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-1014, E-MEXP-2241
glutamine
2
E-MEXP-941, E-MEXP-1335
placebo
2
E-MEXP-1327, E-MEXP-1335
4,5-dianilinophthalimide
1
1
E-GEOD-5258
no estradiol
1
E-GEOD-20081
phoshate buffered saline
1
E-GEOD-3720
34 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
36
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-1563, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-4922

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-6207, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-GEOD-20540, E-MEXP-1446, E-GEOD-22278, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (32 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12254, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11886

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.475 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM